Expression and functional characterization of mutated glucocerebrosidase alleles causing Gaucher disease in Spanish patients

被引:20
|
作者
Alfonso, P [1 ]
Rodríguez-Rey, JC
Gañán, A
Pérez-Calvo, JI
Giralt, M
Giraldo, P
Pocoví, M
机构
[1] Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, Zaragoza, Spain
[2] Univ Cantabria, Unidad Biomed CSIC, Dept Biol Mol, Grp Biol Mol Apolipoprot & Aterosclerisis, Santander, Spain
[3] Hosp Clin Univ Lozano Blesa, Med Interna Serv, Zaragoza, Spain
[4] Hosp Univ Miguel Servet, Hematol Serv, Zaragoza, Spain
关键词
glucocerebrosidase gene; site-directed mutagenesis; transfection; COS cells; residual enzyme activity;
D O I
10.1016/j.bcmd.2003.10.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Gaucher disease (GD) is a heterogeneous disease characterized by an impaired activity of the lysosomal glucocerebrosidase. This heterogeneity is attributed in part to the existence of a large number of mutations in the corresponding gene. Subjects and methods: To establish genotype-phenotype relationships, we analyzed the residual enzyme activities of six naturally occurring mutations found in Spanish population in the glucocerebrosidase gene [c.160G > A (V15M), c.485T > C (M123T), c.914C > T (P266L), c.1124T > C (L336P), c. 1207A > C (S364R) and c. 1510-1512delTCT (S465del)]. The mutated genes were subcloned into the mammalian expression vector pCR(R) 3.1 and expressed by transient transfection in COS cells. The enzymatic activity of the expressed protein were measured and compared with the wild-type human glucocerebrosidase cDNA. Also, two previously alleles, c. 1226A > G (N370S) and c. 1448T > C (L444P), were used for comparative purposes. Results: The residual activity of the expressed proteins using the synthetic substrate (4-methylumbelliferyl-beta-D-glucopyranoside, 4MU-Glu) ranged from 5.5% (for the 3-bp deletion) to 42.7% (for S364R mutation) of the activity of the wild-type enzyme. Conclusion: The present analyses may help to better understand the molecular basis and the pathogenesis of Gaucher disease. However, results of expression of mutated enzymes are necessary but not sufficient to explain the ultimate clinical outcome of Gaucher disease. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:218 / 225
页数:8
相关论文
共 50 条
  • [41] Genotype/phenotype relationship in Gaucher disease patients. Novel mutation in glucocerebrosidase gene
    Lepe-Balsalobre, Esperanza
    Santotoribio, Jose D.
    Nunez-Vazquez, Ramiro
    Garcia-Morillo, Salvador
    Jimenez-Arriscado, Pilar
    Hernandez-Arevalo, Paula
    Delarosa-Rodriguez, Rocio
    Guerrero, Juan M.
    Macher, Hada C.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (12) : 2017 - 2024
  • [42] HIGH-LEVEL TRANSCRIPTION OF THE GLUCOCEREBROSIDASE PSEUDOGENE IN NORMAL SUBJECTS AND PATIENTS WITH GAUCHER DISEASE
    SORGE, J
    GROSS, E
    WEST, C
    BEUTLER, E
    JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (04): : 1137 - 1141
  • [43] Functional analysis of 13 GBA mutant Alleles identified in Gaucher disease patients:: Pathogenic changes and "modifier" polymorphisms
    Montfort, M
    Chabás, A
    Vilageliu, L
    Grinberg, D
    HUMAN MUTATION, 2004, 23 (06) : 567 - 575
  • [44] Incidence of Malignancies in Gaucher's Disease Patients. Data of Spanish Gaucher's Disease Registry
    Andrade-Campos, Marcio
    Barez, Abelardo
    Noya, Soledad
    Fernandez-Galan, M. Angeles
    Balanzat, Jose
    Garcia-Bragado, F.
    Ibanez, Angela
    Giraldo, Pilar
    BLOOD, 2016, 128 (22)
  • [45] ANALYSIS OF THE IMPACT OF MALIGNANT NEOPLASMS IN PATIENTS WITH GAUCHER DISEASE. SPANISH REGISTRY DATA OF GAUCHER DISEASE
    Campos Marcio M, Andrade
    Barez, A.
    Noya Pereira, M. S.
    Fernandez Galan, M. A.
    Garcia, Bragado Dalmau F.
    Garcia Frade, J.
    Ibanez, A.
    Pilar, Giraldo
    HAEMATOLOGICA, 2016, 101 : 293 - 293
  • [46] A NEW GLUCOCEREBROSIDASE-GENE MISSENSE MUTATION RESPONSIBLE FOR NEURONOPATHIC GAUCHER DISEASE IN JAPANESE PATIENTS
    KAWAME, H
    ETO, Y
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (06) : 1378 - 1380
  • [47] Population pharmacokinetic of enzymatic activity of glucocerebrosidase in Gaucher disease patients treated with enzyme replacement therapy
    Gras-Colomer, Elena
    Mangas-Sanjuan, Victor
    Climente-Marti, Monica
    Merino-Sanjuan, Matilde
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S68 - S68
  • [48] Phase I/II study of glucocerebrosidase replacement therapy in patients with type I Gaucher disease
    Zimran, A
    Elstein, D
    Loveday, K
    Aliski, W
    Fratazzi, C
    ACTA PAEDIATRICA, 2006, 95 : 143 - 143
  • [49] Molecular analysis of Turkish Gaucher disease patients:: Identification of novel mutations in glucocerebrosidase (GBA) gene
    Emre, Serap
    Gurakan, Figen
    Yuce, Aysel
    Rolf, Arnold
    Scott, Ronald
    Ozen, Hasan
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2008, 51 (04) : 315 - 321
  • [50] Identification of Pharmacological Chaperones for Gaucher Disease and Characterization of Their Effects on β-Glucocerebrosidase by Hydrogen/Deuterium Exchange Mass Spectrometry
    Tropak, Michael B.
    Kornhaber, Gregory J.
    Rigat, Brigitte A.
    Maegawa, Gustavo H.
    Buttner, Justin D.
    Blanchard, Jan E.
    Murphy, Cecilia
    Tuske, Steven J.
    Coales, Stephen J.
    Hamuro, Yoshitomo
    Brown, Eric D.
    Mahuran, Don J.
    CHEMBIOCHEM, 2008, 9 (16) : 2650 - 2662